Federal regulators on Aug. 25 said they’ve suspended approval for a vaccine against chikungunya, a mosquito-borne virus.
Due to reports of serious adverse events following administration of the vaccine, the Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) “believes this vaccine is not safe and that continued administration to the public would pose a danger to health,” the FDA said in a statement.
France-based Valneva makes the vaccine, known as Ixchiq.
“As we determine potential next steps, and as the clear threat of chikungunya continues to escalate globally, Valneva remains fully committed to maintaining access to our vaccine as a global health tool for addressing and preventing outbreaks of this devastating illness,” Thomas Lingelbach, Valneva’s CEO, said in a statement….